LETTER TO THE EDITOR
Fetal gene therapy for neurodegenerative lysosomal storage diseases
Julien Baruteau,
Simon N. Waddington,
Julien Baruteau
Gene Transfer Technology Group, Institute for Women's Health, University College London, London, UK
Metabolic Medicine Department, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK
Genetics and Genomic Medicine Programme, Great Ormond Street Institute of Child Health, University College London, London, UK
Search for more papers by this authorSimon N. Waddington
Gene Transfer Technology Group, Institute for Women's Health, University College London, London, UK
Wits/SAMRC Antiviral Gene Therapy Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
Search for more papers by this authorJulien Baruteau,
Simon N. Waddington,
Julien Baruteau
Gene Transfer Technology Group, Institute for Women's Health, University College London, London, UK
Metabolic Medicine Department, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK
Genetics and Genomic Medicine Programme, Great Ormond Street Institute of Child Health, University College London, London, UK
Search for more papers by this authorSimon N. Waddington
Gene Transfer Technology Group, Institute for Women's Health, University College London, London, UK
Wits/SAMRC Antiviral Gene Therapy Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
Search for more papers by this authorCommunicating Editor: Carla E. Hollak
No abstract is available for this article.
REFERENCES
- 1Heron B, Valayannopoulos V, Baruteau J, et al. Miglustat therapy in the French cohort of paediatric patients with Niemann-pick disease type C. Orphanet J Rare Dis. 2012; 7: 36.
- 2Ory DS, Ottinger EA, Farhat NY, et al. Intrathecal 2-hydroxypropyl-beta-cyclodextrin decreases neurological disease progression in Niemann-pick disease, type C1: a non-randomised, open-label, phase 1-2 trial. Lancet. 2017; 390: 1758-1768.
- 3Schulz A, Ajayi T, Specchio N, et al. Study of intraventricular Cerliponase alfa for CLN2 disease. N Engl J Med. 2018; 378: 1898-1907.
- 4Tardieu M, Zerah M, Husson B, et al. Intracerebral administration of adeno-associated viral vector serotype rh.10 carrying human SGSH and SUMF1 cDNAs in children with mucopolysaccharidosis type IIIA disease: results of a phase I/II trial. Hum Gene Ther. 2014; 25: 506-516.
- 5Mattar CNZ, Gil-Farina I, Rosales C, et al. In utero transfer of adeno-associated viral vectors produces long-term factor IX levels in a Cynomolgus macaque model. Mol Ther. 2017; 25: 1843-1853.
- 6Karda R, Buckley SM, Mattar CN, et al. Perinatal systemic gene delivery using adeno-associated viral vectors. Front Mol Neurosci. 2014; 7: 89.
- 7Massaro G, Mattar CNZ, Wong AMS, et al. Fetal gene therapy for neurodegenerative disease of infants. Nat Med. 2018; 24: 1317-1323.
- 8Stirnemann J, Belmatoug N, Camou F, et al. A review of Gaucher disease pathophysiology, clinical presentation and treatments. Int J Mol Sci. 2017; 18:441.
- 9Nalysnyk L, Rotella P, Simeone JC, Hamed A, Weinreb N. Gaucher disease epidemiology and natural history: a comprehensive review of the literature. Hematology. 2017; 22: 65-73.
- 10Mignot C, Doummar D, Maire I, De Villemeur TB. French type 2 Gaucher disease study G (2006) type 2 Gaucher disease: 15 new cases and review of the literature. Brain Develop. 2006; 28: 39-48.
- 11Finn LS, Zhang M, Chen SH, Scott CR. Severe type II Gaucher disease with ichthyosis, arthrogryposis and neuronal apoptosis: molecular and pathological analyses. Am J Med Genet. 2000; 91: 222-226.
10.1002/(SICI)1096-8628(20000320)91:3<222::AID-AJMG13>3.0.CO;2-# CAS PubMed Web of Science® Google Scholar
- 12Enquist IB, Lo Bianco C, Ooka A, et al. Murine models of acute neuronopathic Gaucher disease. Proc Natl Sci USA. 2007; 104: 17483-17488.
- 13Mendell JR, Al-Zaidy S, Shell R, et al. Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med. 2017; 377: 1713-1722.
- 14Rangarajan S, Walsh L, Lester W, et al. AAV5-factor VIII gene transfer in severe hemophilia a. N Engl J Med. 2017; 377: 2519-2530.
- 15Dahl M, Doyle A, Olsson K, et al. Lentiviral gene therapy using cellular promoters cures type 1 Gaucher disease in mice. Mol Ther. 2015; 23: 835-844.
- 16Du S, Ou H, Cui R, et al. Delivery of Gba gene using AAV9 vector therapy as a treatment strategy in mouse models of Gaucher disease. Hum Gene Ther. 2018. In Press.
- 17McEachern KA, Nietupski JB, Chuang WL, et al. AAV8-mediated expression of glucocerebrosidase ameliorates the storage pathology in the visceral organs of a mouse model of Gaucher disease. J Gene Med. 2006; 8: 719-729.
- 18Themis M, Schneider H, Kiserud T, et al. Successful expression of beta-galactosidase and factor IX transgenes in fetal and neonatal sheep after ultrasound-guided percutaneous adenovirus vector administration into the umbilical vein. Gene Ther. 1999; 6: 1239-1248.
- 19Couzin J. RAC confronts in utero gene therapy proposals. Science. 1998; 282: 27.
- 20Moulton G. Panel finds in utero gene therapy proposal is premature. J Natl Cancer Inst. 1999; 91: 407-408.
- 21Yoshida S, Kido J, Matsumoto S, et al. Prenatal diagnosis of Gaucher disease using next-generation sequencing. Pediatr Int. 2016; 58: 946-949.
- 22Gort L, Granell MR, Fernandez G, Carreto P, Sanchez A, Coll MJ. Fast protocol for the diagnosis of lysosomal diseases in nonimmune hydrops fetalis. Prenat Diagn. 2012; 32: 1139-1142.
- 23Goker-Alpan O, Hruska KS, Orvisky E, et al. Divergent phenotypes in Gaucher disease implicate the role of modifiers. J Med Genet. 2005; 42: e37.
- 24Gupta N, Oppenheim IM, Kauvar EF, Tayebi N, Sidransky E. Type 2 Gaucher disease: phenotypic variation and genotypic heterogeneity. Blood Cells Mol Dis. 2011; 46: 75-84.
- 25Beutler E, Grabowski GA. Gaucher disease. The Metabolic and Molecular Bases of Inherited Disease. New York, NY: McGraw-Hill; 2001: 3635-3668.
- 26Hammond SL, Leek AN, Richman EH, Tjalkens RB. Cellular selectivity of AAV serotypes for gene delivery in neurons and astrocytes by neonatal intracerebroventricular injection. PLoS One. 2017; 12: e0188830.
- 27Hinderer C, Katz N, Buza EL, et al. Severe toxicity in nonhuman primates and piglets following high-dose intravenous administration of an adeno-associated virus vector expressing human SMN. Hum Gene Ther. 2018; 29: 285-298.
- 28Hordeaux J, Wang Q, Katz N, Buza EL, Bell P, Wilson JM. The neurotropic properties of AAV-PHP.B are limited to C57BL/6J mice. Mol Ther. 2018; 26: 664-668.
- 29Coutelle C, Douar AM, Colledge WH, Froster U. The challenge of fetal gene therapy. Nat Med. 1995; 1: 864-866.
- 30 Gene Therapy Advisory Committee. Report on the potential use of gene therapy in utero. Health departments of the United Kingdom. 1998. Hum Gene Ther; 10: 689-692.
